Royalty Pharma raises 2026 Portfolio Receipts guidance to $3.4 bln-$3.5 bln from $3.325 bln-$3.45 bln
Company expects 2026 Royalty Receipts growth of 7%-10%
Overview
US biopharma royalty investor's Q2 Royalty Receipts grew 14%, Portfolio Receipts up 6% yr/yr
Adjusted EBITDA for Q2 beat analyst expectations
Company raised full-year 2026 guidance for Portfolio Receipts
Result Drivers
Product performance - Growth in Royalty Receipts was primarily driven by Tremfya, Voranigo, Imdelltra and Evrysdi
Generic competition - Declines from Promacta due to U.S. generic competition and from Imbruvica partially offset gains
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Royalty Pharma PLC is $62.22, about 8.2% above its August 4 closing price of $57.48
RPRX•
